|
|
Regenerative Medicine
|
A range of cell types are being developed for potential regeneration of heart, bone, cartilage, nerve and other tissues. While unmodified cells may prove satisfactory in some applications, the ability to introduce into the cell a bioactive molecule, usually a gene construct or an mRNA, greatly increases the potential of the cell-based approach, e.g., by upregulation of angiogenic or targeting activity, or suppression of an apoptotic pathway. MaxCyte's computer-controlled, flow electroporation system can load a wide range of biologically active molecules into primary cells and cell lines. It can do this with consistency, without added chemical or biological reagents, using a closed and sterile processing assembly that can be integrated into a cGMP manufacturing process. The system can expedite translation of regenerative applications from bench to commercialization by avoiding regulatory hurdles associated with other methods.
- Modifying Stem Cells for Clinical Regenerative Applications, Burrill Stem Cell Report [Click Here]
- PAH Cell Therapy, Circulation Res. [Click Here]
- Northern Therapeutics & MaxCyte initiate Landmark Engineered Cell Therapy trial for PAH [Click Here]
|
|
))